HWAM
MDGL icon

Hennion & Walsh Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Hennion & Walsh Asset Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.66M Buy
8,684
+68
+0.8% +$34.8K 0.13% 198
2026
Q1 		$4.51M Buy
8,616
+453
+6% +$216K 0.15% 170
2025
Q4 		$4.75M Sell
8,163
-4,684
-36% -$2.39M 0.16% 154
2025
Q3 		$5.89M Buy
12,847
+172
+1% +$64.2K 0.21% 104
2025
Q2 		$3.84M Buy
12,675
+1,666
+15% +$496K 0.15% 162
2025
Q1 		$3.65M Buy
11,009
+1,105
+11% +$363K 0.16% 162
2024
Q4 		$3.06M Sell
9,904
-9,013
-48% -$2.54M 0.14% 186
2024
Q3 		$4.01M Sell
18,917
-1,420
-7% -$363K 0.19% 132
2024
Q2 		$5.7M Sell
20,337
-11,981
-37% -$2.85M 0.29% 67
2024
Q1 		$8.63M Buy
32,318
+5,392
+20% +$1.27M 0.46% 31
2023
Q4 		$6.23M Sell
26,926
-9,046
-25% -$1.58M 0.36% 52
2023
Q3 		$5.25M Sell
35,972
-1,622
-4% -$305K 0.34% 59
2023
Q2 		$8.68M Sell
37,594
-9,085
-19% -$2.46M 0.52% 30
2023
Q1 		$11.3M Buy
46,679
+736
+2% +$201K 0.69% 18
2022
Q4 		$13.3M Sell
45,943
-5,064
-10% -$495K 0.82% 11
2022
Q3 		$3.31M Sell
51,007
-8,336
-14% -$579K 0.22% 122
2022
Q2 		$4.25M Sell
59,343
-14,391
-20% -$1.06M 0.26% 95
2022
Q1 		$7.24M Buy
73,734
+4,473
+6% +$377K 0.38% 62
2021
Q4 		$5.87M Sell
69,261
-4,675
-6% -$384K 0.29% 96
2021
Q3 		$5.9M Buy
73,936
+372
+0.5% +$32.1K 0.31% 78
2021
Q2 		$7.17M Buy
73,564
+1,222
+2% +$145K 0.38% 60
2021
Q1 		$8.46M Buy
+72,342
New +$8.43M 0.51% 33

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Hennion & Walsh Asset Management's MDGL Position: Q2 2026 in Review

Hennion & Walsh Asset Management increased its Madrigal Pharmaceuticals (MDGL) stake by 0.79% in Q2 2026, buying an estimated $34.8K and bringing the position to 8,684 shares worth $4.66M. The position accounts for 0.13% of the portfolio, ranked #198.

Hennion & Walsh Asset Management first reported a position in MDGL in Q1 2021 and has held it in 22 quarters since. The position peaked at $13.3M in Q4 2022. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Hennion & Walsh Asset Management held 8,684 shares of Madrigal Pharmaceuticals worth $4.66M as of Q2 2026.
  • Hennion & Walsh Asset Management bought 68 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $34.8K.
  • Madrigal Pharmaceuticals made up 0.13% of Hennion & Walsh Asset Management's portfolio in Q2 2026, its #198 holding.
  • Hennion & Walsh Asset Management first reported a position in Madrigal Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
  • Hennion & Walsh Asset Management's Madrigal Pharmaceuticals position peaked at $13.3M in Q4 2022.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.